Your browser doesn't support javascript.
loading
How to handle off-label prescriptions of rupatadine, a second-generation antihistamine and PAF antagonist: a review.
Izquierdo, Iñaki; Casas, Laia; Cabrera, Susana; Fernandez, Alberto.
Afiliação
  • Izquierdo I; Medical Advice Department, BIOHORM S.L., Palau-Solità i Plegamans, Barcelona, Spain.
  • Casas L; Clinical & Preclinical Development, Strategy and Innovation Department, BIOHORM S.L., Palau-Solità i Plegamans, Barcelona, Spain.
  • Cabrera S; Pharmacovigilance Department, NOUCOR HEALTH, S.A., Palau-Solità i Plegamans, Barcelona, Spain.
  • Fernandez A; Pharmacovigilance Department, NOUCOR HEALTH, S.A., Palau-Solità i Plegamans, Barcelona, Spain.
Drugs Context ; 132024.
Article em En | MEDLINE | ID: mdl-38264404
ABSTRACT
The off-label use of second-generation antihistamines, used outside of the formal indications authorized by regulatory authorities, in different age groups, doses or in special populations, is very common for many allergic, autoimmune and dermatological diseases. The off-label use of rupatadine (a second-generation antihistamine with PAF antagonist activity) in these conditions is reviewed here, including in combination with immunotherapy in the treatment of food allergy or allergic rhinitis, at high doses in chronic urticaria, and with prescriptions of less common but challenging conditions such as skin pruritus or mast cell activation disorders like mastocytosis. Rupatadine use is reviewed herein to confirm if its off-label management is supported by well-designed clinical trials or by published real-world cases. This review will contribute to increasing compliance and achieving better results in clinical practice. Off-label use of rupatadine should be left to the discretion of the prescribing healthcare professional after careful clinical evaluation.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Drugs Context Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Espanha País de publicação: Reino Unido

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Drugs Context Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Espanha País de publicação: Reino Unido